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Abstract:  Fms-like tyrosine kinase 3 (Flt3) is a receptor on common stem cell 
progenitors and has a crucial role in hematopoesis, regulating cell proliferation and 
differentiation in man and mice. The growth factor Flt3 is activated by its soluble ligand, Flt3-
L, leading to differentiation of multipotent stem cells and lymphoid progenitors. Flt3-L 
functions as a differentiation factor for dendritic cells (DC) in the periphery. These properties 
of the Flt3/Flt3-L system lead us to further investigate the role of the growth factor Flt3-L in 
rheumatic disease. 
In paper I, Flt3-L was found to be strongly expressed at the site of 
inflammation in human RA, the joint. Levels of Flt3-L were significantly higher in the 
synovial fluid compared to serum in RA patients and levels of Flt3-L in RA synovial fluid 
were significantly higher compared to synovial fluid from non-inflammatory joint diseases. 
Furthermore, intra-articular administration of a B-cell line overexpressing Flt3-L resulted in 
highly erosive arthritis while inoculation of the same B-cell line without hyperexpression of  
Flt3-L did not induce erosivity and caused arthritis in a minority of cases. Thus, Flt3-L is 
expressed at the site of inflammation in human RA and facilitates tissue destructive properites 
in the joint cavity. 
In paper II, mice with antigen-induced arthritis, mBSA-arthritis, were treated 
with the Flt3-inhibitor sunitinib. Treatment was started together with mBSA immunization or 
together with the induction of arthritis. Abrogation of Flt3 signalling reduced the intensity of 
synovitis and the frequency of bone destruction. Inhibition of Flt3 reduced also the number of 
differentiated (mature) dendritic cells concomitant with reduction of antibody production and 
bone metabolism. In addition to this, we investigated the ability of mouse bone marrow cells to 
migrate towards Flt3-L in a migration assay. Flt3-L was found to be a potent chemoattractant 
facilitating mobilization of Flt3+ cells from the bone marrow. Thus, the processes of antigen 
presentation, influx of leukocytes into synovial tissue and bone remodelling are mediated by 
Flt3 signalling in antigen-induced arthritis. 
In paper III, Flt3-L in CSF correlated to levels of Tau and pTau of patients 
with Sjögrens syndrome, fibromyalgia and Alzheimers disease, implying involvement of Flt3L 
in brain homeostasis. Furthermore, CSF Flt3-L in pSS correlated to a marker for microglia 
activation, MCP-1. Levels of Flt3-L in CSF were significantly decreased in pSS, and AD, 
compared to FM.  Low levels of Flt3-L were associated to low levels of amyloid degradation 
peptides in pSS and AD patients. Thus, in CNS of patients with pSS Flt3-L is strongly 
correlated to neuroaxonal plasticity and microglia activation and reduced levels of CSF-Flt3-L 
in pSS are linked to changes in tau and amyloid turnover resembling processes ongoing in AD 
patients. 
Taken together, these results indicate that Flt3-L is involved in the 
inflammatory and tissue remodelling processes in joints and neuroaxonal structures of the 
brain. Flt3/Flt3-L signalling is an essential regulator of antigen-induced processes in 
autoimmune diseases.  
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